Publications by authors named "Claire Dees"

Claim this Profile
P
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).
Liza C Villaruz, Jingxiao Jin, Hong Wang, James J Lee, Jason J Luke, E Claire Dees

Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
Erika Hamilton, Timothy Pluard, Judy S Wang, Aki Morikawa, Stephen Johnston, E Claire Dees

Breast Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival in patients with hormone receptor-positive, HER2-negative advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, E Claire Dees

Lancet Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
Kim A Reiss, Mathew G Angelos, E Claire Dees, Yuan Yuan, Naoto T Ueno

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study.
Sara M Tolaney, Komal Jhaveri, Teresa Helsten, Shannon L Puhalla, Alison Conlin, E Claire Dees

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers, Claire Dees

Breast Cancer Res Treat· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer.
Danielle M File, Yara Abdou, Jeremy Force, Dominic T Moore, Carey K Anders, E Claire Dees

Clin Breast Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Petros Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal, E Claire Dees

Clin Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
Rachel M Layman, Hyo S Han, Hope S Rugo, Erica M Stringer-Reasor, Jennifer M Specht, E Claire Dees

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial.
Brian D Lehmann, Vandana G Abramson, E Claire Dees, Payal D Shah, Tarah J Ballinger

JAMA Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Benjamin G Vincent, Danielle M File, Karen P McKinnon, Dominic T Moore, Jeffrey A Frelinger, E Claire Dees

J Immunol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana, Elizabeth Claire Dees

Cancer Res Commun· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects.
Zev M Nakamura, Allison M Deal, Eliza M Park, Kate E Stanton, Yesy E Lopez, E Claire Dees

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.
Kirsten A Nyrop, Jane Monaco, Sanah Vohra, Allison M Deal, William A Wood, E Claire Dees

Support Care Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Scott A Tomlins, Nickolay A Khazanov, Benjamin J Bulen, Daniel H Hovelson, Melissa J Shreve, E Claire Dees

Commun Med (Lond)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013.
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, Ina Chen, Donald W Northfelt, E Claire Dees

NPJ Breast Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer.
Danielle M File, Tomas Pascual, Allison M Deal, Amy Wheless, Charles M Perou, E Claire Dees

Breast Cancer Res Treat· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer.
Natalia Mitin, Kirsten A Nyrop, Susan L Strum, Anne Knecht, Lisa A Carey, E Claire Dees

NPJ Breast Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.
Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, E Claire Dees

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Sara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, Alison Conlin, E Claire Dees

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies.
Sarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, Richard Kefford, Tara Gangadhar, Claire E Dees

Invest New Drugs· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.
R Donald Harvey, Kathryn F Mileham, Vishal Bhatnagar, Jamie R Brewer, Atiqur Rahman, E Claire Dees

Clin Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer.
Kirsten A Nyrop, Allison M Deal, Yi Tang Chen, Bryce B Reeve, Ethan M Basch, E Claire Dees

Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Breast Cancer Adjuvant Chemotherapy Regimens on Expression of the Aging Biomarker, .
Shlomit S Shachar, Allison M Deal, Katherine E Reeder-Hayes, Kirsten A Nyrop, Natalia Mitin, E Claire Dees

JNCI Cancer Spectr· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
Peter H O'Donnell, Vassily Trubetskoy, Ashley Nurhussein-Patterson, Julianne P Hall, Aritro Nath, E Claire Dees

Breast Cancer Res Treat· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis